References
- 1. M. J. Davies, D. A. D’Alessio, J. Fradkin, W. N. Kernan, C. Mathieu, G. Mingrone, P. Rossing, A. Tsapas, D. J. Wexler and J. B. Buse, Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD), Diabetes Care 41 (2018) 2669–2701; https://doi.org/10.2337/dci18-003310.2337/dci18-0033624520830291106
- 2. Slovenian Endocrinology Association, Slovenian Guidelines on Type 2 Diabetes Management 2016 [in Slovene]; https://endodiab.si/priporocila/smernice-za-vodenje-sladkorne-bolezni/; last access date November 30, 2020.
- 3. P. Home, M. Riddle, W. T. Cefalu, C. J. Bailey, R. G. Bretzel, S. Del Prato, D. Leroith, G. Schernthaner, L. van Gaal and I. Raz, Insulin therapy in people with type 2 diabetes: opportunities and challenges? Diabetes Care 37 (2014) 1499–1508; https://doi.org/10.2337/dc13-274310.2337/dc13-2743513188424855154
- 4. M. D. Campbell, D. Babic, U. Bolcina, L. Smirčić-Duvnjak, T. Tankova, A. Mitrakou, P. Kempler and A. Janez, High level of clinical inertia in insulin initiation in type 2 diabetes across Central and South-Eastern Europe: insights from SITIP study, Acta Diabetol. 56 (2019) 1045–1049; https://doi.org/10.1007/s00592-019-01346-110.1007/s00592-019-01346-1667575330993528
- 5. G. Goodall, E. M. Sarpong, C. Hayes and W. J. Valentine, The consequences of delaying insulin initiation in UK type 2 diabetes patients failing oral hyperglycaemic agents: a modelling study, BMC Endocr. Disord. 9 (2009) Article ID 19 (9 pages); https://doi.org/10.1186/1472-6823-9-1910.1186/1472-6823-9-19276191319804622
- 6. T. Albreht, R. Pribaković Brinovec, D. Jošar, M. Poldrugovac, T. Kostnapfel, M. Zaletel, D. Panteli and A. Maresso, Slovenia: Health system review, Health Syst. Trans. 18 (2016) (207 pages); https://www.euro.who.int/_data/assets/pdf_file/0018/312147/HiT-Slovenia_rev3.pdf; last access date February 15, 2021.
- 7. E. Chiefari, B. Arcidiacono, D. Foti and A. Brunetti, Gestational diabetes mellitus: an updated overview, J. Endocrinol. Invest. 40 (2017) 899–909; https://doi.org/10.1007/s40618-016-0607-510.1007/s40618-016-0607-528283913
- 8. O. Montvida, J. Shaw, J. J. Atherton, F. Stringer and S. K. Paul, Long-term trends in antidiabetes drug usage in the U.S.: Real-world evidence in patients newly diagnosed with type 2 diabetes, Diabetes Care 41 (2018) 69–78; https://doi.org/10.2337/dc17-141410.2337/dc17-141429109299
- 9. S. Wilkinson, I. Douglas, H. Stirnadel-Farrant, D. Fogarty, A. Pokrajac, L. Smeeth and L. Tomlinson, Changing use of antidiabetic drugs in the UK: trends in prescribing 2000-2017, BMJ Open 8 (2018) e022768; https://doi.org/10.1136/bmjopen-2018-02276810.1136/bmjopen-2018-022768606740030056393
- 10. M. Sharma, I. Nazareth and I. Petersen, Trends in incidence, prevalence and prescribing in type 2 diabetes mellitus between 2000 and 2013 in primary care: a retrospective cohort study, BMJ Open 6 (2016) e010210; https://doi.org/10.1136/bmjopen-2015-01021010.1136/bmjopen-2015-010210473517626769791
- 11. A. Ringborg, P. Lindgren, D. D. Yin, M. Martinell and J. Stalhammar, Time to insulin treatment and factors associated with insulin prescription in Swedish patients with type 2 diabetes, Diabetes Metab. 36 (2010) 198–203; https://doi.org/10.1016/j.diabet.2009.11.00610.1016/j.diabet.2009.11.00620347376
- 12. F. Persson, J. Bodegard, J. T. Lahtela, T. Nystrom, M. E. Jorgensen, M. L. Jensen, H. L. Gulseth, M. Thuresson, F. Hoti, D. Nathanson, A. Norhammar, K. I. Birkeland, J. G. Eriksson and J. W. Eriksson, Different patterns of second-line treatment in type 2 diabetes after metformin mono-therapy in Denmark, Finland, Norway and Sweden (D360 Nordic): A multinational observational study, Endocrinol. Diabetes Metab. 1 (2018) e00036; https://doi.org/10.1002/edm2.3610.1002/edm2.36635481730815564
- 13. K. Kostev and W. Rathmann, Changes in time to insulin initiation in type 2 diabetes patients: a retrospective database analysis in Germany and UK (2005-2010), Prim. Care Diabetes 7 (2013) 229–233; https://doi.org/10.1016/j.pcd.2013.03.00310.1016/j.pcd.2013.03.00323608219
- 14. J. M. van den Heuvel, N. Farzan, M. van Hoek, A.-H. Maitland-van der Zee and F. Ahmadizar, Mining treatment patterns of glucose-lowering medications for type 2 diabetes in the Netherlands, BMJ Open Diabetes Res. Care 8 (2020) e000767; https://doi.org/10.1136/bmjdrc-2019-00076710.1136/bmjdrc-2019-000767695478231958296
- 15. T. Wilke, N. Picker, S. Mueller, S. Geier, J. Foersch, J. Aberle, S. Martin, M. Riedl and M. Gabler, Real-world insulin therapy in German type 2 diabetes mellitus patients: patient characteristics, treatment patterns, and insulin dosage, Diabetes Metab. Syndr. Obes. 12 (2019) 1225–1237; https://doi.org/10.2147/DMSO.S21428810.2147/DMSO.S214288666432031440070
- 16. Y. Xu, S. J. Pilla, G. C. Alexander and I. B. Murimi, Use of non-insulin diabetes medicines after insulin initiation: A retrospective cohort study, PLoS One 14 (2019) e0211820; https://doi.org/10.1371/journal.pone.021182010.1371/journal.pone.0211820637395330759121
- 17. K. Khunti, T. Damci, L. Meneghini, C. Y. Pan and J.-F. Yale, Study of once daily levemir (SOLVETM): insights into the timing of insulin initiation in people with poorly controlled type 2 diabetes in routine clinical practice, Diabetes Obes. Metab. 14 (2012) 654–661; https://doi.org/10.1111/j.1463-1326.2012.01602.x10.1111/j.1463-1326.2012.01602.x22443213
- 18. D. C. Beachler, G. Fernandes, G. Deshpande, J. Jemison, L. G. Lyons, S. Lanes, J. Liu and A. Mc-Neill, Patient and prescriber characteristics among patients with type 2 diabetes mellitus continuing or discontinuing sulfonylureas following insulin initiation: data from a large commercial database, Curr. Med. Res. Opin. 34 (2018) 1061–1069; https://doi.org/10.1080/03007995.2017.141634810.1080/03007995.2017.141634829264933
- 19. K. Khunti, M. B. Gomes, S. Pocock, M. V. Shestakova, S. Pintat, P. Fenici, N. Hammar and J. Medina, Therapeutic inertia in the treatment of hyperglycaemia in patients with type 2 diabetes: A systematic review, Diabetes Obes. Metab. 20 (2018) 427–437; https://doi.org/10.1111/dom.1308810.1111/dom.13088581323228834075